Share This Article:

Taq1B CETP Polymorphism and Cardiovascular Risk in an Endogamous Pop-ulation of Diabetic Men: A Study in Santa Rosa Del Conlara, San Luis, Argentina

Full-Text HTML XML Download Download as PDF (Size:451KB) PP. 123-134
DOI: 10.4236/jdm.2015.52015    2,497 Downloads   2,785 Views  


Objectives: Type 2 diabetes mellitus (T2DM) patients are at increased risk of cardiovascular diseases (CVDs). Several polymorphisms in the cholesterol ester transfer protein (CETP) gene have been reported. The aim of this study was to determine the distribution and effect of the Taq1B polymorphism in the CETP gene on clinical and biochemical indicators of CVD risk in a population of endogamous-T2DM men. Methods: 102 men (57.5 ± 9.3 years old) inhabitants of Santa Rosa del Conlara, San Luis, Argentina, were recruited and assigned into two groups (22 control and 80 T2DM). Further, these two groups were subdivided according to their Taq1B CETP gene genotypes (i.e., B1B1, B1B2 and B2B2). Clinical and fasting-plasma biochemical indicators of CVD risk were measured and their association with the B1 allele was determined. Results: Compared to control, T2DM men had more central obesity, hypertension, atherogenic index, insulin resistance and poorly controlled diabetes. Compared to T2DM men having the B2 allele, those T2DM men having the B1 allele have increased risk of CVD as assessed by systolic blood pressure (156 ± 16.0 vs 135.8 ± 19.2, p = 0.015), atherogenic index (6.15 ± 1.3 vs 4.4 ± 0.7, p = 0.0008), HDL-c levels (38.9 ± 5.3 vs 64.4 ± 8.2, p < 0.0001) and insulin resistance (HOMA-IR, 5.78 ± 3.0 vs 2.4 ± 0.78, p = 0.004). Interestingly, only body mass index (r = 0.559, p = 0.01) and HDL-c concentration (r = 0.492, p = 0.02) negatively correlated with CVD risk in the endogamous population of B1B1 and B1B2 T2DM men. Conclusion: The B1 allele of the CETP gene predicts cardiovascular complications in an endogamous population of T2DM men.

Cite this paper

Siewert, S. , Gonzalez, I. , Filipuzzi, S. , Ramirez, D. and Ojeda, M. (2015) Taq1B CETP Polymorphism and Cardiovascular Risk in an Endogamous Pop-ulation of Diabetic Men: A Study in Santa Rosa Del Conlara, San Luis, Argentina. Journal of Diabetes Mellitus, 5, 123-134. doi: 10.4236/jdm.2015.52015.


[1] Pyorala, K., Laakso, M. and Uusitupa, M. (1987) Diabetes and Atherosclerosis: An Epidemiologic View. Diabetes/ Metabolism Reviews, 3, 463-524.
[2] Thompson, J.F., Durham, L.K., Lira, M.E., Shear, C. and Milos, P.M. (2005) CETP Polymorphisms Associated with HDL Cholesterol May Differ from Those Associated with Cardiovascular Disease. Atherosclerosis, 181, 45-53.
[3] Groener, J.E., Van Rozen, A.J. and Erkelens, D.W. (1984) Cholesteryl Ester Transfer Activity. Localization and Role in Distribution of Cholesteryl Ester among Lipoproteins in Man. Atherosclerosis, 50, 261-271.
[4] Thompson, A., Di Angelantonio, E., Sarwar, N., et al. (2008) Association of Cholesteryl Ester Transfer Protein Genotypes with CETP Mass and Activity, Lipid Levels, and Coronary Risk. JAMA, 299, 2777-2788.
[5] Oliveira, H.C., Ma, L., Milne, R., et al. (1997) Cholesteryl Ester Transfer Protein Activity Enhances Plasma Cholesteryl Ester Formation. Studies in CETP Transgenic Mice and Human Genetic CETP Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 1045-1052.
[6] Chaaba, R., Hammami, S., Attia, N., et al. (2005) Association of Plasma Cholesteryl Ester Transfer Protein Activity and Polymorphism with Coronary Artery Disease Extent in Tunisian Type II Diabetic Patients. Clinical Biochemistry, 38, 373-378.
[7] Mohammadpour, A.H. and Akhlaghi, F. (2013) Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective. Clinical Pharmacokinetics, 52, 615-626.
[8] Fielding, C.J. and Havel, R.J. (1996) Cholesteryl Ester Transfer Protein: Friend or Foe? The Journal of Clinical Investigation, 97, 2687-2688.
[9] Ridker, P.M., Pare, G., Parker, A.N., Zee, R.Y., Miletich, J.P. and Chasman, D.I. (2009) Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis among 18,245 Initially Healthy Women from the Women’s Genome Health Study. Circulation: Cardiovascular Genetics, 2, 26-33.
[10] Heidema, A.G., Feskens, E.J., Doevendans, P.A., et al. (2007) Analysis of Multiple SNPs in Genetic Association Studies: Comparison of Three Multi-Locus Methods to Prioritize and Select SNPs. Genetic Epidemiology, 31, 910-921.
[11] Yamashita, S., Hirano, K., Sakai, N. and Matsuzawa, Y. (2000) Molecular Biology and Pathophysiological Aspects of Plasma Cholesteryl Ester Transfer Protein. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1529, 257-275.
[12] Rejeb, J., Omezzine, A., Boumaiza, I., et al. (2012) Four Polymorphisms of Cholesteryl Ester Transfer Protein Gene and Coronary Stenosis in a Tunisian Population. Journal of Cardiovascular Medicine, 13, 546-553.
[13] Brousseau, M.E., O’Connor Jr., J.J., Ordovas, J.M., et al. (2002) Cholesteryl Ester Transfer Protein Taq IB2B2 Genotype Is Associated with Higher HDL Cholesterol Levels and Lower Risk of Coronary Heart Disease End Points in Men with HDL Deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1148-1154.
[14] Robins, S.J., Lyass, A., Brocia, R.W., Massaro, J.M. and Vasan R.S. (2013) Plasma Lipid Transfer Proteins and Cardiovascular Disease. The Framingham Heart Study. Atherosclerosis, 228, 230-236.
[15] Riemens, S., van Tol, A., Sluiter, W. and Dullaart, R. (1998) Elevated Plasma Cholesteryl Ester Transfer in NIDDM: Relationships with Apolipoprotein B-Containing Lipoproteins and Phospholipid Transfer Protein. Atherosclerosis, 140, 71-79.
[16] Heller, D.A., de Faire, U., Pedersen, N.L., Dahlen, G. and McClearn, G.E. (1993) Genetic and Environmental Influences on Serum Lipid Levels in Twins. The New England Journal of Medicine, 328, 1150-1156.
[17] Corsetti, J.P., Ryan, D., Rainwater, D.L., Moss, A.J., Zareba, W. and Sparks, C.E. (2010) Cholesteryl Ester Transfer Protein Polymorphism (TaqIB) Associates with Risk in Postinfarction Patients with High C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1657-1664.
[18] Li, Q., Huang, P., He, Q.C., Lin, Q.Z., Wu, J. and Yin, R.X. (2014) Association between the CETP Polymorphisms and the Risk of Alzheimer’s Disease, Carotid Atherosclerosis, Longevity, and the Efficacy of Statin Therapy. Neurobiology of Aging, 35, 1513, e1513-1523.
[19] Sandhofer, A., Tatarczyk, T., Laimer, M., et al. (2008) The Taq1B-Variant in the Cholesteryl Ester-Transfer Protein Gene and the Risk of Metabolic Syndrome. Obesity, 16, 919-922.
[20] Durlach, A., Clavel, C., Girard-Globa, A. and Durlach, V. (1999) Sex-Dependent Association of a Genetic Polymorphism of Cholesteryl Ester Transfer Protein with High-Density Lipoprotein Cholesterol and Macrovascular Pathology in Type II Diabetic Patients. The Journal of Clinical Endocrinology & Metabolism, 84, 3656-3659.
[21] Bener, A., Yousafzai, M.T., Al-Hamaq, A.O., Mohammad, A.G. and Defronzo, R.A. (2013) Parental Transmission of Type 2 Diabetes Mellitus in a Highly Endogamous Population. World Journal of Diabetes, 4, 40-46.
[22] Zeegers, M.P., van Poppel, F., Vlietinck, R., Spruijt, L. and Ostrer, H. (2004) Founder Mutations among the Dutch. European Journal of Human Genetics, 12, 591-600.
[23] Tenkanen, H., Koshinen, P., Kontula, K., et al. (1991) Polymorphisms of the Gene Encoding Cholesterol Ester Transfer Protein and Serum Lipoprotein Levels in Subjects with and without Coronary Heart Disease. Human Genetics, 87, 574-578.
[24] Mitchell, R.J., Earl, L., Williams, J., Bisucci, T. and Gasiamis, H. (1994) Polymorphisms of the Gene Coding for the Cholesteryl Ester Transfer Protein and Plasma Lipid Levels in Italian and Greek Migrants to Australia. Human Biology, 66, 13-25.
[25] Hannuksela, M.L., Liinamaa, M.J., Kesaniemi, Y.A. and Savolainen, M.J. (1994) Relation of Polymorphisms in the Cholesteryl Ester Transfer Protein Gene to Transfer Protein Activity and Plasma Lipoprotein Levels in Alcohol Drinkers. Atherosclerosis, 110, 35-44.
[26] Freeman, D.J., Griffin, B.A., Holmes, A.P., et al. (1994) Regulation of Plasma HDL Cholesterol and Subfraction Distribution by Genetic and Environmental Factors. Associations between the TaqIB RFLP in the CETP Gene and Smoking and Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 14, 336-344.
[27] Kondo, I., Berg, K., Drayna, D. and Lawn, R. (1989) DNA Polymorphism at the Locus for Human Cholesteryl Ester Transfer Protein (CETP) Is Associated with High Density Lipoprotein Cholesterol and Apolipoprotein Levels. Clinical Genetics, 35, 49-56.
[28] Meguro, S., Takei, I., Murata, M., et al. (2001) Cholesteryl Ester Transfer Protein Polymorphism Associated with Macroangiopathy in Japanese Patients with Type 2 Diabetes. Atherosclerosis, 156, 151-156.
[29] The Expert Committee of the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 20, 1183-1197.
[30] Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502.
[31] Fumeron, F., Betoulle, D., Luc, G., et al. (1995) Alcohol Intake Modulates the Effect of a Polymorphism of the Cholesteryl Ester Transfer Protein Gene on Plasma High Density Lipoprotein and the Risk of Myocardial Infarction. The Journal of Clinical Investigation, 96, 1664-1671.
[32] Kawasaki, I., Tahara, H., Emoto, M., Shoji, T. and Nishizawa, Y. (2002) Relationship between TaqIB Cholesteryl Ester Transfer Protein Gene Polymorphism and Macrovascular Complications in Japanese Patients with Type 2 Diabetes. Diabetes, 51, 871-874.
[33] Schierer, A., Been, L.F., Ralhan, S., Wander, G.S., Aston, C.E. and Sanghera, D.K. (2012) Genetic Variation in Cholesterol Ester Transfer Protein, Serum CETP Activity, and Coronary Artery Disease Risk in Asian Indian Diabetic Cohort. Pharmacogenetics and Genomics, 22, 95-104.
[34] McEneny, J., Blair, S., Woodside, J.V., Murray, L., Boreham, C. and Young, I.S. (2013) High-Density Lipoprotein Subfractions Display Proatherogenic Properties in Overweight and Obese Children. Pediatric Research, 74, 279-283.
[35] Hirschler, V., Merono, T., Maccallini, G., Gomez Rosso, L., Aranda, C. and Brites, F. (2011) Impact of Unhealthy Lifestyle Behaviors and Obesity on Cholesteryl Ester Transfer Protein among Adolescent Males. Archives of Medical Research, 42, 53-59.
[36] Ordovas, J.M., Cupples, L.A., Corella, D., et al. (2000) Association of Cholesteryl Ester Transfer Protein-TaqIB Polymorphism with Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk: The Framingham Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1323-1329.
[37] Park, K.W., Choi, J.H., Kim, H.K., et al. (2003) The Association of Cholesteryl Ester Transfer Protein Polymorphism with High-Density Lipoprotein Cholesterol and Coronary Artery Disease in Koreans. Clinical Genetics, 63, 31-38.
[38] Lopez-Rios, L., Perez-Jimenez, P., Martinez-Quintana, E., et al. (2011) Association of Taq1B CETP Polymorphism with Insulin and HOMA Levels in the Population of the Canary Islands. Nutrition, Metabolism & Cardiovascular Diseases, 21, 18-24.
[39] Bruce, C. and Tall, A.R. (1995) Cholesteryl Ester Transfer Proteins, Reverse Cholesterol Transport, and Atherosclerosis. Current Opinion in Lipidology, 6, 306-311.
[40] Lopez-Rios, L., Novoa, F.J., Chirino, R., Varillas, F., Boronat-Cortes, M. and Wagner, A.M. (2011) Interaction between Cholesteryl Ester Transfer Protein and Hepatic Lipase Encoding Genes and the Risk of Type 2 Diabetes: Results from the Telde Study. PLoS ONE, 6, e27208.
[41] Gammon, C.S., Minihane, A.M., Kruger, R., et al. (2014) TaqIB Polymorphism in the Cholesteryl Ester Transfer Protein (CETP) Gene Influences Lipid Responses to the Consumption of Kiwifruit in Hypercholesterolaemic Men. British Journal of Nutrition, 111, 1077-1084.
[42] Stein, O. and Stein, Y. (1999) Atheroprotective Mechanisms of HDL. Atherosclerosis, 144, 285-301.
[43] Bernard, S., Moulin, P., Lagrost, L., et al. (1998) Association between Plasma HDL-Cholesterol Concentration and Taq1B CETP Gene Polymorphism in Non-Insulin-Dependent Diabetes Mellitus. The Journal of Lipid Research, 39, 59-65.
[44] Pillois, X., Phuong Do Thi, N., Reynaud, A., Benchimol, D., Lagrost, L. and Bonnet, J. (2009) TaqIB Polymorphism in Cholesterol Ester Transfer Protein (CETP) Gene Predicts Future Cardiovascular Death in Patients Experiencing an Acute Coronary Syndrome. Clinical Chemistry and Laboratory Medicine, 47, 1039-1046.
[45] Chang, C.K., Tso, T.K., Snook, J.T., Huang, Y.S., Lozano, R.A. and Zipf, W.B. (2001) Cholesteryl Ester Transfer and Cholesterol Esterification in Type 1 Diabetes: Relationships with Plasma Glucose. Acta Diabetologica, 38, 37-42.
[46] de Vries, R., Perton, F.G., Dallinga-Thie, G.M., et al. (2005) Plasma Cholesteryl Ester Transfer Is a Determinant of Intima-Media Thickness in Type 2 Diabetic and Nondiabetic Subjects: Role of CETP and Triglycerides. Diabetes, 54, 3554-3559.
[47] Li, T.Y., Zhang, C., Asselbergs, F.W., et al. (2007) Interaction between Dietary Fat Intake and the Cholesterol Ester Transfer Protein TaqIB Polymorphism in Relation to HDL-Cholesterol Concentrations among US Diabetic Men. The American Journal of Clinical Nutrition, 86, 1524-1529.
[48] Bloomfield, D., Carlson, G.L., Sapre, A., et al. (2009) Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib as Monotherapy and Coadministered with Atorvastatin in Dyslipidemic Patients. American Heart Journal, 157, 352-360.
[49] Krauss, R.M., Pinto, C.A., Liu, Y., Johnson-Levonas, A.O. and Dansky, H.M. (2015) Changes in LDL Particle Concentrations after Treatment with the Cholesteryl Ester Transfer Protein Inhibitor Anacet-rapib Alone or in Combination with Atorvastatin. Journal of Clinical Lipidology, 9, 93-102.
[50] He, B.M., Zhao, S.P. and Peng, Z.Y. (2013) Effects of Cigarette Smoking on HDL Quantity and Function: Implications for Atherosclerosis. Journal of Cellular Biochemistry, 114, 2431-2436.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.